Amgen (AMGN) Stock Forecast & Price Target

Q: What analysts cover Amgen?

Amgen has been rated by research analysts at Argus , Bank of America , Barclays , BMO Capital Markets , Canaccord Genuity Group , Cantor Fitzgerald , Citigroup , Guggenheim , HSBC , Mizuho , Morgan Stanley , Oppenheimer , Piper Sandler , Robert W. Baird , Royal Bank Of Canada , Sanford C. Bernstein , Scotiabank , TD Cowen , Truist Financial , UBS Group , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$377.35 -5.12 (-1.34%)

Closing price 04:00 PM Eastern

Extended Trading

$377.85 +0.50 (+0.13%)

As of 04:59 PM Eastern

Compare

Amgen - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 30 Analyst Ratings

Sell
3

Hold
15

Buy
12

Based on 30 Wall Street analysts who have issued ratings for Amgen in the last 12 months, the stock has a consensus rating of "Hold." Out of the 30 analysts, 3 have given a sell rating, 15 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for AMGN.

Consensus Price Target

$381.68
1.15% Upside

According to the 30 analysts' twelve-month price targets for Amgen, the average price target is $381.68. The highest price target for AMGN is $460.00, while the lowest price target for AMGN is $200.00. The average price target represents a forecasted upside of 1.15% from the current price of $377.35.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for AMGN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Amgen and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AMGN Analyst Ratings Over Time

Type	Current Forecast 9/11/25 to 9/11/26	1 Month Ago 8/12/25 to 8/12/26	3 Months Ago 6/13/25 to 6/13/26	1 Year Ago 9/11/24 to 9/11/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	11 Buy rating(s)	12 Buy rating(s)	13 Buy rating(s)	6 Buy rating(s)
Hold	15 Hold rating(s)	15 Hold rating(s)	14 Hold rating(s)	12 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$381.68	$371.68	$354.12	$304.15
Forecasted Upside	1.15% Upside	-10.69% Downside	-0.31% Downside	7.58% Upside
Consensus Rating	Hold	Hold	Hold	Hold

AMGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AMGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Amgen Stock vs. The Competition

Type	Amgen	Healthcare Companies	Broader Market
Consensus Rating Score	2.33	2.30	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	0.65% Upside	881.95% Upside	16.23% Upside
News Sentiment Rating	Neutral News See Recent AMGN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/10/2026	HSBC 2 of 5 stars	Morten Herholdt Not Rated	Downgrade	Buy ➝ Hold	$445.00 ➝ $425.00	+8.62%
9/8/2026	BMO Capital Markets 3 of 5 stars	Evan David Seigerman 3 of 5 stars	Downgrade	Outperform ➝ Market Perform	$450.00	+2.92%
9/8/2026	Cantor Fitzgerald 5 of 5 stars	Carter Gould 4 of 5 stars	Reiterated Rating	Neutral	$400.00	-8.51%
9/4/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$400.00 ➝ $435.00	-2.05%
8/20/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Amsellem Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$427.00 ➝ $457.00	+3.31%
8/19/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$362.00	-17.81%
8/19/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jasper Hellweg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$375.00 ➝ $460.00	+7.04%
8/18/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Salim Syed Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$303.00 ➝ $352.00	-16.07%
8/14/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emily Field Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$360.00 ➝ $380.00	-9.06%
8/10/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vamil Divan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$343.00 ➝ $388.00	-5.58%
Get the Latest News and Ratings for AMGN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.
8/7/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$345.00 ➝ $405.00	+0.04%
8/6/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Buy (B-) ➝ Buy (B)
8/6/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Courtney Breen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Market Perform	$335.00 ➝ $345.00	-15.41%
8/5/2026	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Louise Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$385.00 ➝ $450.00	+10.82%
8/5/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Yee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$420.00 ➝ $440.00	+7.89%
8/5/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yaron Werber Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$420.00 ➝ $452.00	+11.26%
8/5/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$340.00 ➝ $362.00	-7.33%
8/5/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jay Olson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$400.00 ➝ $450.00	+15.20%
8/5/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luca Issi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$370.00 ➝ $400.00	+2.40%
8/5/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Underperform	$215.00 ➝ $230.00	-41.12%
8/5/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Underperform	$312.00 ➝ $317.00	-18.85%
8/5/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gary Nachman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$366.00 ➝ $384.00	-1.70%
6/5/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$389.00	+9.79%
5/13/2026	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$410.00 ➝ $390.00	+17.59%
5/7/2026	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
5/5/2026	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold
3/10/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Akash Tewari Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy ➝ Hold	$350.00	-7.15%
3/5/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Risinger Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Perform	$355.00	-3.43%
2/18/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Sell	$180.00 ➝ $200.00	-46.43%
2/5/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Hold	$285.00 ➝ $295.00	-19.79%
11/10/2025	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target		$335.00 ➝ $364.00	+13.68%
9/3/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gary Nachman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Market Perform
6/24/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
3/5/2025	Johnson Rice Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$294.00	-10.47%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alexandria Hammond Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Peer Perform
9/16/2024	Dbs Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	N. Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 04:59 PM ET.

Should I Buy Amgen Stock? AMGN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 8, 2026. Please send any questions or comments about these Amgen pros and cons to contact@marketbeat.com.

Amgen
Bull Case

Here are some ways that investors could benefit from investing in Amgen Inc.:

Amgen Inc. reported a significant clinical breakthrough on September 8, 2026, when its Phase 3 DeLLphi-305 trial demonstrated a statistically significant and clinically meaningful improvement in overall survival for IMDELLTRA (tarlatamab) combined with AstraZeneca's Imfinzi in first-line extensive-stage small-cell lung cancer, strengthening the commercial outlook for its oncology pipeline.
The company recently delivered strong financial results in its Q2 2026 earnings report, beating analyst expectations with an EPS of $6.29 compared to a consensus of $5.62 and generating revenue of $10.05 billion, which exceeded the expected $9.43 billion and represented a 9.5% year-over-year increase.
Amgen Inc. offers a stable income stream for investors through its dividend, which currently yields 2.31% based on the current stock price of $393.17, with a recent quarterly declaration of $2.52 per share paid on September 11, 2026.
Analyst sentiment remains cautiously optimistic with a consensus rating of Hold and an average price target of $381.68, while specific firms like William Blair and Leerink Partners have issued Buy ratings, citing the positive read-through from the IMDELLTRA trial success.
The stock exhibits low volatility relative to the broader market with a beta of 0.43, suggesting it may serve as a defensive holding during periods of market turbulence, such as the recent risk-off trading environment driven by geopolitical tensions and rising oil prices.

Amgen
Bear Case

Investors should be bearish about investing in Amgen Inc. for these reasons:

Amgen Inc. shares experienced a sharp decline of approximately 10% on September 8, 2026, falling to $393.17 from a previous close of $437.23, primarily due to negative read-through from Novartis' failed Phase 3 pelacarsen trial, which raised doubts about the efficacy of Amgen's experimental Lp(a) drug olpasiran.
BMO Capital Markets downgraded Amgen Inc. to Market Perform from Outperform on September 8, 2026, citing a more balanced risk-reward profile and limited immediate upside, which reflects growing concerns about the company's near-term growth potential.
Insider selling activity has been notable recently, with Senior Vice Presidents Nancy Grygiel and Rachna Khosla selling a combined 5,222 shares in August 2026, representing a significant reduction in their personal holdings and potentially signaling a lack of confidence in the current stock price.
The company faces a high debt-to-equity ratio of 4.44, which indicates a substantial level of leverage relative to its equity base, potentially increasing financial risk during periods of economic uncertainty or rising interest rates.
Amgen Inc. is exposed to broader market risks, including the recent surge in crude oil prices toward $100 per barrel due to Iran-related tensions, which has contributed to a risk-off trading environment and added pressure to large-cap healthcare stocks.

AMGN Forecast - Frequently Asked Questions

According to the research reports of 30 Wall Street equities research analysts, the average twelve-month stock price forecast for Amgen is $381.68, with a high forecast of $460.00 and a low forecast of $200.00.

30 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 3 sell ratings, 15 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.

According to analysts, Amgen's stock has a predicted upside of 1.15% based on their 12-month stock forecasts.

Over the previous 90 days, Amgen's stock had 3 downgrades and 1 upgrade by analysts.

Amgen has been rated by research analysts at Argus, Bank of America, Barclays, BMO Capital Markets, Canaccord Genuity Group, Cantor Fitzgerald, Citigroup, Guggenheim, HSBC, Mizuho, Morgan Stanley, Oppenheimer, Piper Sandler, Robert W. Baird, Royal Bank Of Canada, Sanford C. Bernstein, Scotiabank, TD Cowen, Truist Financial, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Amgen more than other "healthcare" companies. The consensus rating score for Amgen is 2.33 while the average consensus rating score for "healthcare" companies is 2.30. Learn more on how AMGN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Amgen Recommendations

MarketBeat monitors more than a dozen sources for Amgen analyst ratings, with the most recent rating issued on 9/10/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amgen (AMGN) Stock Forecast & Price Target